TOKYO, Feb 2, 2023 – (JCN Newswire via SEAPRWire. […]
ป้ายกำกับ: study
Lecanemab Receives Priority Review Status in Japan
TOKYO and CAMBRIDGE, Mass., Jan 30, 2023 – (JCN N […]
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer’s Disease in Japan
TOKYO and CAMBRIDGE, Mass., Jan 16, 2023 – (JCN N […]
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease in Europe
TOKYO, Jan 11, 2023 – (JCN Newswire via SEAPRWire […]
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
ROCKVILLE, MD and SHENZHEN, CHINA, Jan 5, 2023 – […]
MHI Signs MoU with Chile’s Guacolda Energia for Feasibility Study of Ammonia Co-Firing at a Coal-Fired Thermal Power Plant
TOKYO, Dec 7, 2022 – (JCN Newswire via SEAPRWire. […]
Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease in the New England Journal of Medicine
TOKYO, Nov 30, 2022 – (JCN Newswire via SEAPRWire […]
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
TOKYO, Nov 30, 2022 – (JCN Newswire via SEAPRWire […]
AJG Publishes Data from HighTide Therapeutics’ Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis
ROCKVILLE, MD and SHENZHEN, CHINA, Nov 17, 2022 – […]
American Journal of Gastroenterology Publishes Data from HighTide Therapeutics’ Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis
ROCKVILLE, MD and SHENZHEN, CHINA, Nov 16, 2022 – […]
Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon
TOKYO, Nov 2, 2022 – (JCN Newswire via SEAPRWire. […]
Eisai Announces Plans to Submit Application for Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies Based on Results of Drug Reexamination
TOKYO, Nov 2, 2022 – (JCN Newswire via SEAPRWire. […]
Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA
HONG KONG, Aug 24, 2022 – (ACN Newswire via SEAPR […]
Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022
TOKYO, Jul 26, 2022 – (JCN Newswire via SEAPRWire […]
TrialWire Technology Platform Rolls Out World First SMS/Text Patient Contact System Across all Studies Globally
ADELAIDE, AUS, Jul 20, 2022 – (ACN Newswire via S […]